{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15"],"submitter":["Lu L"],"funding":["Garnett Passe and Rodney Williams Memorial Foundation","Australian Research Council"],"pubmed_abstract":["Subunit vaccines hold substantial promise in controlling infectious diseases, due to their superior safety profile, specific immunogenicity, simplified manufacturing processes, and well-defined chemical compositions. One of the most important end-targets of vaccines is a subset of lymphocytes originating from the thymus, known as T cells, which possess the ability to mount an antigen-specific immune response. Furthermore, vaccines confer long-term immunity through the generation of memory T cell pools. Dendritic cells are essential for the activation of T cells and the induction of adaptive immunity, making them key for the <i>in vitro</i> evaluation of vaccine efficacy. Upon internalization by dendritic cells, vaccine-bearing antigens are processed, and suitable fragments are presented to T cells by major histocompatibility complex (MHC) molecules. In addition, DCs can secrete various cytokines to crosstalk with T cells to coordinate subsequent immune responses. Here, we generated an <i>in vitro</i> model using the immortalized murine dendritic cell line, DC2.4, to recapitulate the process of antigen uptake and DC maturation, measured as the elevation of CD40, MHC-II, CD80 and CD86 on the cell surface. The levels of key DC cytokines, tumor necrosis alpha (TNF-α) and interleukin-10 (IL-10) were measured to better define DC activation. This information served as a cost-effective and rapid proxy for assessing the antigen presentation efficacy of various vaccine formulations, demonstrating a strong correlation with previously published <i>in vivo</i> study outcomes. Hence, our assay enables the selection of the lead vaccine candidates based on DC activation capacity prior to <i>in vivo</i> animal studies."],"journal":["Frontiers in immunology"],"pagination":["1298721"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10925716"],"repository":["biostudies-literature"],"pubmed_title":["Utilizing murine dendritic cell line DC2.4 to evaluate the immunogenicity of subunit vaccines <i>in vitro</i>."],"pmcid":["PMC10925716"],"pubmed_authors":["Lu L","Toth I","Skwarczynski M","Zhang J","Wells JW","Stephenson RJ","Firdaus F","Cruz JLG","Kong WY"],"additional_accession":[]},"is_claimable":false,"name":"Utilizing murine dendritic cell line DC2.4 to evaluate the immunogenicity of subunit vaccines <i>in vitro</i>.","description":"Subunit vaccines hold substantial promise in controlling infectious diseases, due to their superior safety profile, specific immunogenicity, simplified manufacturing processes, and well-defined chemical compositions. One of the most important end-targets of vaccines is a subset of lymphocytes originating from the thymus, known as T cells, which possess the ability to mount an antigen-specific immune response. Furthermore, vaccines confer long-term immunity through the generation of memory T cell pools. Dendritic cells are essential for the activation of T cells and the induction of adaptive immunity, making them key for the <i>in vitro</i> evaluation of vaccine efficacy. Upon internalization by dendritic cells, vaccine-bearing antigens are processed, and suitable fragments are presented to T cells by major histocompatibility complex (MHC) molecules. In addition, DCs can secrete various cytokines to crosstalk with T cells to coordinate subsequent immune responses. Here, we generated an <i>in vitro</i> model using the immortalized murine dendritic cell line, DC2.4, to recapitulate the process of antigen uptake and DC maturation, measured as the elevation of CD40, MHC-II, CD80 and CD86 on the cell surface. The levels of key DC cytokines, tumor necrosis alpha (TNF-α) and interleukin-10 (IL-10) were measured to better define DC activation. This information served as a cost-effective and rapid proxy for assessing the antigen presentation efficacy of various vaccine formulations, demonstrating a strong correlation with previously published <i>in vivo</i> study outcomes. Hence, our assay enables the selection of the lead vaccine candidates based on DC activation capacity prior to <i>in vivo</i> animal studies.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-06-27T03:15:17.474Z","creation":"2025-04-04T21:30:51.948Z"},"accession":"S-EPMC10925716","cross_references":{"pubmed":["38469294"],"doi":["10.3389/fimmu.2024.1298721"]}}